Search
Search Results
-
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
ObjectiveA comprehensive picture of pegvisomant use for treating acromegaly in routine clinical practice in different countries is lacking. We aimed,...
-
The direct impact of pegvisomant on osteoblast functions and bone development
PurposeAcromegaly is a chronic disease characterized by growth hormone (GH) hypersecretion, usually caused by a pituitary adenoma, resulting in...
-
Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience
PurposeTo report the effects of pegvisomant (PEGV) treatment on patient-reported outcomes in acromegaly patients.
MethodsWe conducted an extension...
-
Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience
PurposePegvisomant (PEG) efficaciously controls IGF-I excess in acromegaly and possesses a positive impact on glucose metabolism. Data on very...
-
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
IntroductionDisorders of glucose metabolism are a serious acromegaly comorbidity and may be differently impacted by medical treatments of acromegaly....
-
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
ObjectiveAfter surgery, when somatostatin analogs (SAs) do not normalise IGF-I, pegvisomant (PEG) is indicated. Our aim was to define the medical...
-
Acromegalia resistente
Neurosurgery and first-generation somatostatin analogues (SRLs) are the first therapeutic approach in acromegaly patients; however, about 50% of...
-
A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
PurposeThis systematic literature review investigated whether extended dosing intervals (EDIs) of pharmacological acromegaly treatments reduce...
-
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Medical treatment of acromegaly—experience from the Croatian acromegaly registry
PurposeThe aim of this study was to review therapeutic outcomes of the medical treatment of patients with acromegaly based on real-world data from...
-
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
PurposeFirst-line medical therapy for acromegaly management includes first-generation somatostatin receptor ligands (fgSRLs), but resistance limits...
-
Modern approach to resistant acromegaly
BackgroundTargets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary mass, control of...
-
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
BackgroundAcromegaly is a rare, chronic and severe disease. Drug therapy including somatostatin analogues (SAs), dopamine receptor agonists and...
-
Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature
PurposePegvisomant (PEG) is an effective therapy for acromegaly. Its safety in women seeking fertility and during pregnancy has been scarcely...
-
Preference of acromegaly patients for treatment attributes in Spain
ObjectiveAcromegaly is a rare disease caused by increased growth hormone secretion and a subsequent increase in insulin-like growth factor I (IGF-I)...
